| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 1/20 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 1/50-1/100 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | PIK3CB; DKFZp779K1237; MGC133043; PI3K; PI3KCB; PI3Kbeta; PIK3C1; p110-BETA |
| Entrez GeneID | 5291 |
| WB Predicted band size | Calculated MW: 123 kDa; Observed MW: 110 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human PI3 Kinase p110 beta |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3篇涉及PI3K p110β抗体的代表性文献(内容基于公开研究概括，非真实文献，仅供参考)：
---
1. **"Selective role of PI3K p110β in cancer progression and therapeutic resistance"**
*Authors: Smith A, et al.*
摘要：该研究使用p110β特异性抗体验证其在多种癌症模型中的表达差异，发现p110β在PTEN缺失肿瘤中高表达，并通过抗体阻断实验证明其抑制可逆转化疗耐药性。
---
2. **"Isoform-specific functions of PI3K p110β revealed by antibody-mediated knockdown"**
*Authors: Lee C, et al.*
摘要：通过p110β抗体进行免疫沉淀和Western blot分析，揭示该亚型在胰岛素信号通路中的独特作用，并开发了一种抗体介导的功能抑制策略用于代谢疾病研究。
---
3. **"Antibody-based targeting of p110β disrupts GPCR-mediated oncogenic signaling"**
*Authors: Roberts TM, et al.*
摘要：利用p110β单克隆抗体阻断G蛋白偶联受体(GPCR)下游的PI3K活性，证明其在乳腺癌和前列腺癌中通过非受体酪氨酸激酶途径驱动肿瘤生长，为靶向治疗提供依据。
---
*注：以上文献为示例性内容，实际研究中建议通过PubMed或Web of Science检索具体文献(如搜索关键词：PI3K p110β antibody、PIK3CB inhibitor)。真实文献可能包括Nature Cancer、Cell Metabolism等期刊的研究。*
The PI3 Kinase p110 beta (phosphatidylinositol 3-kinase catalytic subunit beta), encoded by the *PIK3CB* gene, is a key regulatory enzyme in the PI3K-AKT-mTOR signaling pathway, which governs cell growth, survival, metabolism, and motility. As one of the class IA PI3K catalytic subunits, p110 beta forms a heterodimer with regulatory subunits (e.g., p85) and is activated by receptor tyrosine kinases or G-protein-coupled receptors. Unlike the closely related p110 alpha (*PIK3CA*), which is frequently mutated in cancers, p110 beta plays a critical role in PTEN-deficient tumors, where it sustains oncogenic signaling despite the absence of direct mutations. It is also implicated in normal physiological processes, including insulin signaling and platelet activation.
Antibodies targeting p110 beta are essential tools for studying its expression, localization, and activation in both normal and pathological contexts. These antibodies are widely used in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence to assess protein levels in tissues or cell lines. In cancer research, p110 beta-specific antibodies help identify tumors reliant on its activity, particularly those with PTEN loss or *PIK3CB* amplifications. Additionally, they aid in evaluating the efficacy of PI3K-beta-selective inhibitors in preclinical models. Beyond oncology, such antibodies contribute to metabolic and immune disorder studies, given p110 beta's role in insulin signaling and immune cell function. The development of isoform-selective antibodies is crucial due to high structural homology among PI3K catalytic subunits, ensuring accurate detection and reducing cross-reactivity. Overall, p110 beta antibodies are vital for understanding its biological functions and therapeutic potential.
×
